Search research articles
Contact Us
Filters
Showing results (191-200 of 223) with videos related to
Page
of 23
Sort By:
Biomaterials Advances
|
July 1, 2026
Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models
Claudia Cocchi, Valentina Bergamini, Monica Montesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Plos One
|
November 9, 2013
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey
Nicola Silvestris, Francesco Pantano, Toni Ibrahim, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 26, 2021
Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients
Salvatore Alfieri, Rebecca Romanò, Marco Bologna, et al.
Frontiers in Oncology
|
December 26, 2022
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a <i>post-hoc</i> analysis
Emanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Cancer Medicine
|
May 27, 2017
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
Rossana Berardi, Mariangela Torniai, Sara Pusceddu, et al.
Plos One
|
January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey
Daniele Santini, Giuseppe Procopio, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Journal of Neuroendocrinology
|
November 19, 2025
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management
Nicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 223) with videos related to
Sort By:
Page
of 23
Biomaterials Advances
|
July 1, 2026
Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models
Claudia Cocchi, Valentina Bergamini, Monica Montesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
Plos One
|
November 9, 2013
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey
Nicola Silvestris, Francesco Pantano, Toni Ibrahim, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 26, 2021
Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients
Salvatore Alfieri, Rebecca Romanò, Marco Bologna, et al.
Frontiers in Oncology
|
December 26, 2022
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a <i>post-hoc</i> analysis
Emanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Cancer Medicine
|
May 27, 2017
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
Rossana Berardi, Mariangela Torniai, Sara Pusceddu, et al.
Plos One
|
January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey
Daniele Santini, Giuseppe Procopio, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca, et al.
Journal of Neuroendocrinology
|
November 19, 2025
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management
Nicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, et al.
Page
of 23